Alpine BioVentures

[Alpine BioVentures @AlpineBV]

News from one of our portfolio companies this morning.

[Angion Biomedica @AngionBiomedica]

.@ViforPharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications. More here: https://t.co/TEE7MnpVuN

[Alpine BioVentures @AlpineBV]

Great news from @AlpineImmuneSci and @abbvie! The licensing agreement, which has the potential to be the largest autoimmune deal on record, provides the necessary resources to maximize ALPN-101’s potential for autoimmune diseases, accelerating the ALPN-202 and ALPN-30x programs.

[Hussein Tawbi, MD, PhD @HTawbi_MDPhD]

Great step forward- need to harmonize our definitions of the clinical phenotypes of resistance to propel #immunotherapy drug development in this space... @sitcancer bringing the community together...

[Alpine BioVentures @AlpineBV]

Listen to ABV co-founder Mitch Gold in this wide-ranging #WhatFuelsYou #podcast talking about raising his family, what motivates him, and how he thinks about the future. https://t.co/TCAvJsDKcC

[Alpine BioVentures @AlpineBV]

We are excited to see @AbbVie advance @MavuPharma first-in-class, orally active, small molecule inhibitor of ENPP1. STING pathway stimulation has the potential to expand the accessibility of tumors and broaden treatment options for patients.

https://t.co/RSQZPbOHd0

[Alpine BioVentures @AlpineBV]

Congratulations to the @MavuPharma team, an Alpine BioVentures and @FrazierHealth co-investment, for its acquisition by @AbbVie https://t.co/5HArQPHimN

[Alpine BioVentures @AlpineBV]

Congratulations to the @MavuPharma team, an Alpine BioVentures and @FrazierHealth co-investment, for its acquisition by @AbbVie https://t.co/5HArQPHimN

[Alpine BioVentures @AlpineBV]

@RetroNewsNow @LuckyCharms Happy 55th birthday to my nearly-every-morning companion, Lucky

[Alpine BioVentures @AlpineBV]

All of us at ABV wish you peace, prosperity, and happiness in this new year. We're excited to see what 2018 has in store!

[Alpine BioVentures @AlpineBV]

Excited to join @FrazierHealth in Mavupharma's $20M Series A round funding what we hope will be another advance in the treatment of cancer.

https://t.co/qZdes2JJET

[Alpine BioVentures @AlpineBV]

We seed funded $ALPN and joined OrbiMed and Frazier Healthcare Partners in the Series A. Exciting morning!

https://t.co/OXQYdCc3et

[AlpineImmuneSciences @AlpineImmuneSci]

We start trading today under $ALPN on @Nasdaq
Nivalis merger is closed. Exciting science in #immunotherapy to come!

[Alpine BioVentures @AlpineBV]

Congrats to @AlpineImmuneSci on proposed merger with $NVLS We're joining @OrbiMed & @FrazierHealth in $17M expected investment at closing

[Alpine BioVentures @AlpineBV]

Our portfolio company is looking for great people to join their team.

https://t.co/GCinqYCoul

[AlpineImmuneSciences @AlpineImmuneSci]

Alpine Immune Sciences is hiring. Position descriptions and a contact link are on our Careers page: https://t.co/UhDhDAGYEE

[Alpine BioVentures @AlpineBV]

Which calls into question how we run trials and approve drugs. Rooting for basket trial successes!
https://t.co/0EgQXxvb8g

[Christina Meyer @ChristinaYalie]

The immune system doesn't care about histology of the cancer--only the immune environment, antigens, etc #SITC2015

[AlpineImmuneSciences @AlpineImmuneSci]

Proud to partner with @KitePharma scientists on the next-generation of engineered cellular therapies. https://t.co/IBo83Iixpn

[Alpine BioVentures @AlpineBV]

@Alpine_Mitch on the panel.
http://t.co/efS4XxQxiX

[Alpine BioVentures @AlpineBV]

Alpine's Managing Director @Alpine_Mitch panel on increasing efficiency in drug development starts now. #WarOnCancer

[Alpine BioVentures @AlpineBV]

Dr. Jay Venkatesan joins Alpine BioVentures as Managing Partner. http://t.co/S7HBOo2nU8

[AlpineImmuneSciences @AlpineImmuneSci]

Our website is now live. We look forward to helping patients with cancer and autoimmune disease. http://t.co/JKrzB6jiux